Literature DB >> 6269000

In vitro studies on 6-fluoronoradrenaline at several peripheral sympathetic neuroeffector junctions.

N B Shepperson, T Purcell, R Massingham, S Z Langer.   

Abstract

A comparison of the effects of noradrenaline and 6-fluoronoradrenaline has been made at several peripheral sympathetic neuroeffector junctions. In the rat vas deferens preparation in the presence of 1 microM cocaine, 6-fluoronoradrenaline was found to be about 9 times more potent than noradrenaline as an agonist at presynaptic inhibitory alpha 2- adrenoceptors. In the rabbit aorta, 6-fluoronoradrenaline had approximately one tenth of the potency of noradrenaline in stimulating the postsynaptic alpha 1-adrenoceptors. Furthermore 6-fluoronoradrenaline, in contrast to previous reports, appears to be a substrate for the neuronal uptake process since exposure to cocaine potentiated the inhibition of the twitch response of the vas deferens by 6-fluoronoradrenaline. In addition, 6-fluoronoradrenaline increased the spontaneous outflow of radioactivity from rabbit pulmonary artery strips prelabelled with 3H-noradrenaline and this increase was blocked by cocaine (30 microM). These results demonstrate that 6-fluoronoradrenaline is a preferential alpha 2-adrenoceptor agonist which is a substrate for the neuronal uptake process in peripheral sympathetically innervated smooth muscle preparations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6269000     DOI: 10.1007/bf00506247

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  Pharmacological characterisation of the presynaptic alpha-adrenoceptor in the rat vas deferens.

Authors:  G M Drew
Journal:  Eur J Pharmacol       Date:  1977-03-21       Impact factor: 4.432

2.  Effect of fluorine substitution on the agonist specificity of norepinephrine.

Authors:  D Cantacuzene; K L Kirk; D H McCulloh; C R Creveling
Journal:  Science       Date:  1979-06-15       Impact factor: 47.728

3.  Preferential blockade of presynaptic alpha-adrenoceptors by yohimbine.

Authors:  K Starke; E Borowski; T Endo
Journal:  Eur J Pharmacol       Date:  1975-12       Impact factor: 4.432

4.  Relative pre- and postsynaptic potencies of alpha-adrenoceptor agonists in the rabbit pulmonary artery.

Authors:  K Starke; T Endo; H D Taube
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

5.  The effect of hydrocortisone on the sensitivity of the isolated nictitating membrane to catecholamines: Relationship to extraneuronal uptake and metabolism.

Authors:  K H Graefe; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Preferential metabolism of (-) 3 H-norepinephrine through the deaminated glycol in the rat vas deferens.

Authors:  K H Graffe; F J Stefano; S Z Langer
Journal:  Biochem Pharmacol       Date:  1973-05-15       Impact factor: 5.858

7.  Fluoronorepinephrines: specific agonists for the activation of alpha and beta adrenergic-sensitive cyclic AMP-generating systems in brain slices.

Authors:  J W Daly; W Padgett; Y Nimitkitpaisan; C R Creveling; D Cantacuzene; K L Kirk
Journal:  J Pharmacol Exp Ther       Date:  1980-03       Impact factor: 4.030

8.  Synthesis and biological properties of 2-, 5-, and 6-fluoronorepinephrines.

Authors:  K L Kirk; D Cantacuzene; Y Nimitkitpaisan; D McCulloh; W L Padgett; J W Daly; C R Creveling
Journal:  J Med Chem       Date:  1979-12       Impact factor: 7.446

9.  Postsynaptic alpha-adrenoceptor subtypes in rabbit blood vessels and rat anococcygeus muscle studied in vitro.

Authors:  J R Docherty; K Starke
Journal:  J Cardiovasc Pharmacol       Date:  1981 Jul-Aug       Impact factor: 3.105

  9 in total
  1 in total

1.  Differential blocking actions of idazoxan against the inhibitory effects of 6-fluoronoradrenaline and clonidine in the rat vas deferens.

Authors:  P E Hicks; S Z Langer; A D Macrae
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.